Form 4: Caris Life Sciences Director Peter Castleman Reports Significant Equity Changes Following Reverse Stock Split and IPO

Caris Life Sciences Director Peter M. Castleman has reported changes in his beneficial ownership, including the conversion of preferred stock into common stock and the award of restricted stock units, following a one-for-four reverse stock split and the company's initial public offering.

Summary

• Peter M. Castleman, a Director of Caris Life Sciences, Inc., reported changes in his beneficial ownership of the company's securities.
• On February 27, 2025, Castleman was awarded 16,129 restricted stock units (RSUs) of Common Stock at a price of $0, which vest according to the applicable grant agreement.
• On the same date, he acquired 2,500 direct stock options with an exercise price of $18.6, which are fully vested and exercisable, expiring on February 27, 2035.
• On June 20, 2025, 40,983,607 shares of Series A Preferred Stock held indirectly by CLS-PF-SPE, LLC were automatically converted into 10,245,906 shares of Common Stock upon the closing of Caris Life Sciences' initial public offering.
• All reported securities reflect a one-for-four reverse stock split that became effective on June 1, 2025.
• Following these transactions, Castleman directly beneficially owns 16,129 shares of Common Stock and 2,500 stock options.
• Indirectly, he beneficially owns 10,270,906 shares of Common Stock through CLS-PF-SPE, LLC and 100,000 shares of Common Stock through a Family Trust.

Sentiment

Score: 6

Explanation: The document is a standard Form 4 reporting insider transactions, including RSU awards, stock option grants, and preferred stock conversion following an IPO and reverse stock split. These are routine corporate actions and insider equity adjustments, not indicative of immediate positive or negative operational performance. The awards and conversions are generally seen as positive for management alignment and liquidity.

Positives

• Award of 16,129 restricted stock units (RSUs) to a director, aligning management's interests with shareholders.
• Grant of 2,500 fully vested and exercisable stock options to a director.
• Successful conversion of preferred stock into common stock upon the closing of the initial public offering, indicating a significant corporate milestone.

Negatives

• No explicit negative information is present in this Form 4 filing.

Risks

• No specific risks are detailed in this Form 4 filing, which primarily reports insider transactions.

Future Outlook

The filing primarily reports past and current insider transactions and does not provide explicit forward-looking statements or guidance regarding the company's future performance or strategic direction, beyond the implication of the recent initial public offering.

Management Comments

• Represents an award of restricted stock units which vest in accordance with the applicable grant agreement.
• All the securities reported in this Form 4 reflect a one-for-four reverse stock split effected as of June 1, 2025.
• Each share of preferred stock automatically converted into 0.25 shares of Common Stock of the Issuer upon the closing of the initial public offering of the Issuer's Common Stock.
• The stock option is fully vested and exercisable.
• The Reporting Person disclaims beneficial ownership except to the extent of his pecuniary interest therein.

Industry Context

This Form 4 filing reflects standard post-IPO equity adjustments and insider ownership reporting for a life sciences company. The conversion of preferred stock to common stock is a typical event following an initial public offering, allowing early investors and insiders to convert their equity into publicly tradable shares. The reverse stock split is a corporate action often undertaken to increase share price and meet listing requirements, common in the biotechnology and life sciences sectors.

Comparison to Industry Standards

• The one-for-four reverse stock split is a common corporate action, often seen in biotech or life sciences companies like Caris Life Sciences, to increase share price and potentially meet exchange listing requirements, similar to actions taken by companies such as Sorrento Therapeutics (SRNE) or Aeterna Zentaris (AEZS) in the past to maintain stock price above minimum thresholds.
• The automatic conversion of preferred stock upon IPO closing is a standard mechanism for venture capital or private equity investors to realize their investment in a public company, comparable to the conversion events seen in the IPOs of other growth-stage biotech firms like Moderna (MRNA) or BioNTech (BNTX) where early investor preferred shares converted to common stock.
• The award of restricted stock units (RSUs) and stock options to a director is a standard form of equity compensation, aligning management incentives with shareholder value, consistent with compensation practices at peer companies in the diagnostic and precision medicine space such as Guardant Health (GH) or Exact Sciences (EXAS).

Related Party Transactions

• Peter M. Castleman's indirect beneficial ownership through CLS-PF-SPE, LLC, where he is a manager of the managing entity (CLS-PF-SPE Manager, LLC) and has voting and investment power, constitutes a related party arrangement for reporting purposes, though beneficial ownership is disclaimed except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The reverse stock split impacts the number of shares outstanding and per-share price, while the conversion of preferred stock increases the float of common shares. Insider equity awards align director interests with shareholder value.
• Employees: No direct impact on employees is mentioned in this filing.
• Customers: No direct impact on customers is mentioned in this filing.
• Suppliers: No direct impact on suppliers is mentioned in this filing.
• Creditors: No direct impact on creditors is mentioned in this filing.

Next Steps

• Continued vesting of the 16,129 restricted stock units according to the applicable grant agreement.
• Potential exercise of the 2,500 stock options by Peter M. Castleman prior to their expiration on February 27, 2035.
• Ongoing reporting of any further changes in beneficial ownership by Peter M. Castleman via future Form 4 filings.

Key Dates

Recommendation

Keywords

Caris Life Sciences, SEC Form 4, Beneficial Ownership, Insider Trading, Restricted Stock Units, Stock Options, Preferred Stock Conversion, Reverse Stock Split, Initial Public Offering, Peter M. Castleman, Equity Compensation, Corporate Governance